Theravance's Gut-Selective JAK Inhibitor Disappoints In Ulcerative Colitis Study
Crohn's Disease Data Awaited On Izencitinib
Top-line results from a Phase IIb study of Theravance’s potential gut-selective JAK inhibitor izencitinib have not matched expectations, and results from a similar early-stage study in Crohn’s disease with the Janssen-partnered candidate are now awaited at the end of the year or in early 2022.
